Trial Wins Boost Eli Lilly In Cymbalta Cases As MDL Bid Looms

By Sindhu Sundar (September 2, 2015, 9:17 PM EDT) -- Eli Lilly & Co.'s third straight trial win over the withdrawal risks of its antidepressant Cymbalta sealed the company's success in persuading a federal jury that warnings on the drug were adequate, a key finding that defense attorneys say gives the drugmaker an edge in an upcoming fight with plaintiffs trying to consolidate dozens of similar suits....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as